Dr. Segal, along with lab members Dr. Jeff Atkinson and PhD student Ashley Munie, traveled to Savannah in January to attend the ACTRIMS Young Scientist Summit. Dr. Segal, a member of ACTRIMS Board of Directors, provided both the Introductory and Closing remarks.
The Segal Lab has published a new (July 16, 2018) paper in the Journal of Neuroinflammation detailing evidence of a previously undiscovered mechanism in which cytokines IFNγ and CXCL2 interact to regulate central nervous system lesion location in an experimental allergic encephalomyelitis (EAE) mouse model. You can read the full abstract via PubMed at this link.
The University of Michigan Multiple Sclerosis Center is awarded the distinction of a “Center of Excellence for Comprehensive Care in MS” by the National Multiple Sclerosis Society.
Research presentations by Neurology Training Grant Awardees Andrew Sas, M.D., Ph.D.
It was surprising for many of us when a well-known actress recently revealed she’s been dealing with multiple sclerosis (MS) for 15 years. Jamie Lynn Sigler said in interviews she was symptom-free for a long time, and now takes medication to keep her symptoms stable.
Dr. Benjamin Segal, Holtom-Garrett Professor of Neurology and director of the U-M Multiple Sclerosis Center, explains that MS treatment has grown by leaps and bounds in the past 20 years.
“I myself have many patients who are high-functioning, successful contributors to society, from CEOs and professors to doctors and lawyers. Many of these individuals have no signs of MS that are apparent to co-workers or acquaintance,” Segal wrote.
Read the full blog: http://uofmhealthblogs.org/neurohealth/a-revolution-in-ms-treatment/27090/